Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.

Sarah M. Cheal,Hong Xu,Hong-Fen Guo,Sang-gyu Lee,Blesida Punzalan,Sandhya Chalasani,Edward K. Fung,Achim A. Jungbluth,Pat Zanzonico,Jorge A. Carrasquillo,Joseph ODonoghue,Peter Smith-Jones,Karl Dane Wittrup,Cheung Nk,Steven M. Larson

Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.

2016

Sarah M. Cheal
Hong Xu
Hong-Fen Guo
Sang-gyu Lee
Blesida Punzalan
Sandhya Chalasani
Edward K. Fung
Achim A. Jungbluth
Pat Zanzonico
Jorge A. Carrasquillo
Joseph ODonoghue
Peter Smith-Jones
Karl Dane Wittrup
Cheung Nk
Steven M. Larson

Purpose GPA33 is a colorectal cancer (CRC) antigen with unique retention properties after huA33-mediated tumor targeting. We tested a pretargeted radioimmunotherapy (PRIT) approach for CRC using a tetravalent bispecific antibody with dual specificity for GPA33 tumor antigen and DOTA-Bn–(radiolanthanide metal) complex.

Keywords:

Tumor antigen
Medicine
Pathology
Antibody
DOTA
Cancer research
Pretargeting
GPA33
Pretargeted Radioimmunotherapy
Immunology
Radioimmunotherapy
Antigen
Colorectal cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations